Medical devices, healthcare technology and the business of care
PMA approval · P170043

iStent inject Trabecular Micro-Bypass System (Model G2-M-IS)

Glaukos Corporation · Decision date Jun 21, 2018

MEDTECHLEDGER EXPLANATIONP170043

What did the FDA approve?

FDA approved the iStent inject Trabecular Micro-Bypass System (Model G2-M-IS) on June 21, 2018, under PMA number P170043. The approval statement describes the device as indicated for use in conjunction with cataract surgery for the reduction of intraocular pressure (IOP) in adult patients with mild to moderate primary open-angle glaucoma.

The applicant is Glaukos Corporation, and the device is classified under product code OGO as an intraocular pressure lowering implant in the ophthalmic specialty. The source statement reports the device's stated purpose but does not itself provide independent evidence of safety or clinical effectiveness. No supplement type or supplement reason is recorded, so the entry appears to reflect the original PMA approval rather than a change to an existing approval.

FDA approval order statement

Approval for the iStent inject Trabecular Micro-Bypass System (Model G2-M-IS). This device is indicated for use in conjunction with cataract surgery for the reduction of intraocular pressure (IOP) in adult patients with mild to moderate primary open-angle glaucoma.
Regulatory pathway
Original PMA
Clinical specialty
Ophthalmic
Decision date
Jun 21, 2018

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P170043
Regulatory pathway
Premarket approval application
Product code
OGO
Decision code
APPR
Decision date
Jun 21, 2018
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Intraocular pressure lowering implant.

Product code
OGO
FDA device class
3

The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.

FDA decision timeline

  1. P170043 received

    Application receipt date recorded by FDA.

  2. P170043 · FDA decision

    APPR

  3. P170043/S023 · Related supplement

    Glaukos iStent inject W Trabecular Micro-Bypass System, Glaukos iStent inject W Trabecular Micro-Bypass System with

Timeline entries are records held by MedtechLedger for P170043. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P170043

Product / regulatory recordCompanyPathwayDecision dateSource
Glaukos CorporationPMA supplementOct 1, 2026FDA

Explore the linked device profile

Regulatory context

An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Glaukos Corporation

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
229 Avenida Fabricante, San Clemente, CA, 92672

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records